Picture someone with a decent employer health plan who has been through three antidepressants in four years. Each one dulled things a little, cost them something in side effects, and eventually stopped being worth it. What they want, if they are honest, is something that is not another pill. There is a real chance their plan already covers one. There is a much bigger chance they have never heard its name.
That gap, between wanting a drug-free option and knowing one exists, is one of the sharpest findings in a survey our publisher commissioned this summer. It is worth walking through, especially if you carry commercial insurance.
The gap in two numbers
The poll reached 443 adults across ten Midwest states. One question paired two ideas: whether respondents knew what TMS, or transcranial magnetic stimulation, is, and whether having a drug-free depression option mattered to them.
Drug-free mattered to 64 percent. Only 25 percent knew what TMS was.
Broken down further, the gap gets plainer still. Just over half of all respondents, 51 percent, fell into a single box: they did not know what TMS was, yet they said drug-free mattered to them. A further 13 percent were already familiar with TMS and put a lot of weight on drug-free care. Twelve percent knew TMS but said drug-free status would not change much for them. The last 25 percent neither knew TMS nor cared much about drug-free.
All of these describe the whole general-population sample, from the final validated data. The commercial breakdown sharpens the point: of the 173 respondents with commercial insurance, 71 percent said a drug-free option mattered.
Why this matters more for commercial plan members
Commercial insurance was the most common kind of coverage in the sample, though only narrowly. On the payer question, which allowed several answers at once, 39 percent reported commercial coverage, just ahead of Medicaid at 37 percent, a near tie. Medicare followed at 23 percent.
The survey did not ask anyone what their plan's TMS policy says. What we can add is practical: many commercial health plans have written coverage policies for TMS in adults whose major depression has not improved on medication, typically requiring prior authorization and documentation of earlier treatment. If you are in that 51 percent who wants drug-free care but has never heard of TMS, your plan's policy may be the most useful document you have not read.
What TMS is, briefly
In transcranial magnetic stimulation, a device positioned against the head delivers magnetic pulses aimed at mood-related regions of the brain. The FDA has cleared it for major depressive disorder in adults who have not improved enough with antidepressant medication. Note the word "cleared," which is how the FDA handles medical devices, as distinct from "approved," the term used for drugs.
A few practical realities:
- You are awake the whole time. No anesthesia is involved.
- Sessions typically happen five days a week over several weeks.
- Most patients can drive to and from sessions on their own.
- Scalp soreness and headaches are the usual complaints. A seizure is uncommon but serious, and clinicians screen for factors that raise it.
- Many people stay on their medication during TMS. "Drug-free" describes the treatment itself, not necessarily your whole regimen. Never stop a medication without your prescriber.
Some people respond and some do not, and nobody can promise it will work for you. Whether you are a candidate is a question for a psychiatrist.
How it compares with esketamine
The other newer option people hear about is esketamine, sold as Spravato, whose FDA approval, as a nasal spray, covers depression that resists treatment. That one is a drug, given only at certified clinics with monitoring after each dose, and the patient cannot drive again until the next day. For someone whose priority is avoiding medication, TMS and esketamine sit at opposite ends of that preference, which is exactly why knowing both exist matters. For the drug side of that comparison, Brain Recovery Centers describes how Spravato treatment works.
Awareness is low across the board. Spravato was unknown to 73 percent of respondents. The newer options, drug and device alike, are largely invisible to the public.
What the rest of the survey says about decision-making
Coverage and approval status carried weight. Insurance coverage was a top-two provider criterion for 85 percent. FDA approval was decisive or weighty for 59 percent, a reminder to ask any TMS provider which device they use and what it is cleared for.
And people trust their doctors. A full 74 percent said their own doctor's encouragement would be what tips them toward something new, while just 12 percent said they would start by searching online. Commercially insured respondents leaned on the doctor even more, at 81 percent. For TMS, that is the core of the gap: if a doctor never mentions it and a patient would never search for it, it stays invisible.
If you want a drug-free option and have commercial insurance
- Ask your doctor directly. "I would like to explore options that are not another medication. Is TMS something I should be evaluated for?"
- Find your plan's TMS policy. Look up your insurer's written medical policy on transcranial magnetic stimulation online, or ask member services to send it. It will list the criteria.
- Gather your history. Plans typically want documentation of prior antidepressant trials, including names, doses, durations, and outcomes, and sometimes psychotherapy.
- Confirm the provider is in network. Ask the TMS practice whether they handle prior authorization.
- Ask about cost-sharing. Deductibles and coinsurance can add up over a multi-week course. Get an estimate before you start.
None of this is medical advice. The goal is simply to make sure an option you might want is not ruled out because nobody ever said its name.
When depression starts steering you toward thoughts of ending your life, the insurance paperwork can wait. Text or dial 988, the Suicide and Crisis Lifeline, whenever it hits, and a trained person will stay with you through it.
Methodology
The publisher commissioned this study with its own funds, and Pollfish handled fielding via its consumer panel, closing the survey on June 23, 2026, having reached n=443 people aged 18 to 64 across Nebraska, Minnesota, Missouri, Kansas, Oklahoma, Iowa, Ohio, Wisconsin, Illinois, and Indiana. Only the commercial insurance numbers describe a subgroup; Pollfish validated every response before these final figures were drawn.